Evolent Health (EVH) Q2 2026 Earnings Call Transcript

Evolent Health (EVH) reported Q2 2026 revenue of $652.5M versus $444.3M a year earlier, citing the Highmark contract launch. Net loss attributable to common shareholders was $28.4M. Adjusted EBITDA was $28.1M. Full-year 2026 revenue guidance was raised to $2.6B-$2.7B and adjusted EBITDA to $120M-$135M. 2027 revenue growth is expected to exceed 25%.

Original reporting
Published Aug 13, 2026, 7:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 7:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Evolent Health (EVH) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$EVHBullishMed
01

Why it matters

The most tradable elements are the raised 2026 guidance ranges, the 2027 growth and adjusted EBITDA outlook, and the planned oncology Performance Suite partnership launch by Dec. 2026, all weighed against explicit membership and margin headwinds.

02

Market read

Guidance upgrades and a large oncology partnership projection are likely to drive re-rating, while margin and membership risks may cap upside and increase volatility.

03

What to watch

Operating cash flow was impacted by about $20M of onetime items, and management flagged membership pressure through 2027, which could pressure near-term leverage and valuation even with guidance raises.

Relevance 8/10Novelty 8/10Timing: post-Q2 earnings call, guidance and 2027 outlook updates for positioning into upcoming quarters

Background

Evolent’s Q2 2026 call centers on scaling its AI authorization platform and expanding Performance Suite contracts, especially tied to the Highmark launch.

Company-level read

Ticker impact

$EVHBullishMedium confidence
Context

Evolent reported Q2 revenue of $652.5M, raised 2026 revenue guidance to $2.6B-$2.7B, and guided 2026 adjusted EBITDA to $120M-$135M.

Expected impact

Near-term bias positive on guidance raise and 2027 growth outlook, with volatility risk if investors focus on margin compression and membership headwinds.

Evidence & confidence

The call includes multiple forward-looking datapoints (raised 2026 ranges, 2027 growth >25%, oncology partnership launch by Dec. 2026) plus explicit risk framing (Medicaid/exchange declines, operating cash flow timing, medical expense ratio increase).

Market effects

Reinforces demand for AI-enabled prior authorization and capitated specialty care management, potentially supporting sentiment toward managed-care tech and value-based specialty platforms.

Blue Cross and Highmark/Aetna partnership execution signals continued payer investment in specialty care management across US regional plans.

Limited direct global impact; primarily US payer-provider operations and reimbursement dynamics.

Counterpoint

The revenue growth mix shift toward higher-growth, lower-margin Performance Suite plus rising medical expense ratio could mean the EBITDA improvement is less durable than investors expect.

Key entities

  • Evolent Health, Inc.

    Subject of the earnings call transcript; reported Q2 results, raised 2026 guidance, and outlined 2027 growth and AI platform scale.

  • Seth Blackley

    CEO who described Q2 as a tipping point for AI scale and discussed 2027 growth absorbing membership declines.

  • Mario Ramos

    CFO who highlighted Medicaid/exchange membership pressure and cash flow impacts from onetime items.

  • Highmark

    Payer partner whose May 1, 2026 launch drove higher Performance Suite membership and revenue contribution in Q2 and expected Q3.

  • Aetna

    Payer referenced for clinical engagement and claims performance trending in line with expectations.

Related articles

$EVHMedAI 8/10

EVH Q3 2026 deep dive: ongoing AI investment and customer expansion shape outlook

EVH reported Q3 2026 revenue of $725.4M (51.3% YoY growth, in line with estimates) and adjusted EPS of $0.06 (in line). Adjusted EBITDA was $34.26M, beating estimates by 3.1%. The company reconfirmed full-year revenue guidance of $2.65B and raised EBITDA guidance to $132.5M. Sales volumes fell 4.2% YoY, while operating margin declined to -0.9%. EVH expanded its AI platform, Oncology care, and National payer scale, citing cost savings and margin expansion potential.

$EVHMed

Evolent Health, Inc. Q3 2026 Earnings Call Summary

Evolent Health reported 11% sequential revenue growth driven by Highmark Performance Suite and contractual adjustments. MER improved to 93%. Management prioritizes margin expansion and cash generation, with oncology expected to represent over 70% of revenue by 2027. AI platform scales, processing 1M cases annually. Management reiterated 2027 Adjusted EBITDA confidence of $150M+ and plans $50M debt reduction by 2026 year-end.

$EVHMedAI 8/10

Evolent Health (EVH) Q3 2026 Earnings Call Transcript

Evolent Health (EVH) reiterated its full-year revenue guidance of $2.6B-$2.7B and raised Adjusted EBITDA guidance to $130M-$135M. The company reported customer contract renewals and expansions, including a 4-year renewal with its largest Surgical Management customer and expansions in oncology and specialty services.

$EVHMed

Evolent Health: Q3 Earnings Snapshot

Evolent Health (EVH) reported a Q3 loss of $23.6M, or 21 cents per share, with adjusted earnings of 6 cents per share, meeting expectations. Revenue was $725.4M, below the $734.3M forecast. The company expects full-year revenue between $2.6B and $2.7B.